Wird geladen...
Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance
We examined an immediate, but short-lived, response to crizotinib, a drug with a new indication for ROS1 rearranged non-small cell lung cancer (NSCLC) in a middle-aged non-smoker. The patient presented with metastatic NSCLC and extensive disease in multiple organs. He was treated with crizotinib 250...
Gespeichert in:
| Veröffentlicht in: | BMJ Case Rep |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMJ Publishing Group
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5093785/ https://ncbi.nlm.nih.gov/pubmed/27797842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2016-217322 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|